From drugs of abuse to parkinsonism. The MPTP mouse model of Parkinson's disease - PubMed (original) (raw)
Review
From drugs of abuse to parkinsonism. The MPTP mouse model of Parkinson's disease
Yuen-Sum Lau et al. Methods Mol Med. 2003.
No abstract available
Similar articles
- Mechanisms of MPTP toxicity.
Przedborski S, Jackson-Lewis V. Przedborski S, et al. Mov Disord. 1998;13 Suppl 1:35-8. Mov Disord. 1998. PMID: 9613716 Review. - 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level.
Kupsch A, Sautter J, Schwarz J, Riederer P, Gerlach M, Oertel WH. Kupsch A, et al. Brain Res. 1996 Nov 25;741(1-2):185-96. doi: 10.1016/s0006-8993(96)00917-1. Brain Res. 1996. PMID: 9001722 - Progression and recovery of Parkinsonism in a chronic progressive MPTP-induction model in the marmoset without persistent molecular and cellular damage.
Franke SK, van Kesteren RE, Wubben JA, Hofman S, Paliukhovich I, van der Schors RC, van Nierop P, Smit AB, Philippens IH. Franke SK, et al. Neuroscience. 2016 Jan 15;312:247-59. doi: 10.1016/j.neuroscience.2015.09.065. Epub 2015 Oct 9. Neuroscience. 2016. PMID: 26431624 - Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism.
Arai N, Misugi K, Goshima Y, Misu Y. Arai N, et al. Brain Res. 1990 May 7;515(1-2):57-63. doi: 10.1016/0006-8993(90)90576-w. Brain Res. 1990. PMID: 2357577 - [Parkinsonism induced by MPTP as an experimental model of Parkinson disease: similarities and differences].
Luquin MR, Obeso JA, Herrero MT, Laguna J, MartÃnez-Lage JM. Luquin MR, et al. Neurologia. 1991 Oct;6(8):287-94. Neurologia. 1991. PMID: 1790005 Review. Spanish.
Cited by
- Influence of intranasal exposure of MPTP in multiple doses on liver functions and transition from non-motor to motor symptoms in a rat PD model.
Datta I, Mekha SR, Kaushal A, Ganapathy K, Razdan R. Datta I, et al. Naunyn Schmiedebergs Arch Pharmacol. 2020 Feb;393(2):147-165. doi: 10.1007/s00210-019-01715-1. Epub 2019 Aug 29. Naunyn Schmiedebergs Arch Pharmacol. 2020. PMID: 31468077 - Neuroprotective effect of long-term NDI1 gene expression in a chronic mouse model of Parkinson disorder.
Barber-Singh J, Seo BB, Nakamaru-Ogiso E, Lau YS, Matsuno-Yagi A, Yagi T. Barber-Singh J, et al. Rejuvenation Res. 2009 Aug;12(4):259-67. doi: 10.1089/rej.2009.0854. Rejuvenation Res. 2009. PMID: 19653878 Free PMC article. - Protection by the NDI1 gene against neurodegeneration in a rotenone rat model of Parkinson's disease.
Marella M, Seo BB, Nakamaru-Ogiso E, Greenamyre JT, Matsuno-Yagi A, Yagi T. Marella M, et al. PLoS One. 2008 Jan 16;3(1):e1433. doi: 10.1371/journal.pone.0001433. PLoS One. 2008. PMID: 18197244 Free PMC article. - Sex differences in motor behavior in the MPTP mouse model of Parkinson's disease.
Antzoulatos E, Jakowec MW, Petzinger GM, Wood RI. Antzoulatos E, et al. Pharmacol Biochem Behav. 2010 Jun;95(4):466-72. doi: 10.1016/j.pbb.2010.03.009. Epub 2010 Mar 27. Pharmacol Biochem Behav. 2010. PMID: 20347863 Free PMC article. - NMR Metabolomics Analysis of Parkinson's Disease.
Lei S, Powers R. Lei S, et al. Curr Metabolomics. 2013;1(3):191-209. doi: 10.2174/2213235X113019990004. Curr Metabolomics. 2013. PMID: 26078917 Free PMC article.